What's Ahead for Healthcare Innovation in 2025
In this special episode, Bessemer Venture Partners’ Healthcare and Life Sciences team shares the top industry developments they anticipate in the year to come, covering:
⚖️ The future of Obamacare exchanges under Trump
💊 Novel drug modalities
📊 Improved GLP-1 payment models
🏥 Caregiver workforce shifts
🤖 Multimodal clinical AI in practice
🔮 And more!
Join Bessemer Partners Steve Kraus and Andrew Hedin, and Vice Presidents Sofia Guerra and Morgan Cheatham, for this special episode on the state of the healthcare business in 2025.
About our guests:
Andrew Hedin, Sofia Guerra, and Morgan Cheatham make up Bessemer Venture Partners’ Healthcare and Life Sciences team, along with HOH co-host, Steve Kraus.
Andrew Hedin:
Andrew Hedin is a partner in Bessemer’s Cambridge office where he focuses on investments broadly across the healthcare ecosystem, including new biotech therapeutics as well as software and services sold to healthcare verticals.
Prior to joining Bessemer in 2015, Andrew worked at F-Prime Capital, Fidelity’s healthcare-focused venture capital fund where he invested in early-stage biotech and digital health technologies, as well as Leerink Partners as an advisor to the biopharma industry.
He earned an MBA with honors from The Wharton School, where he majored in health care management and finance, as well as a degree in biological basis of behavior from the University of Pennsylvania.
Sofia Guerra:
Sofia is a vice president at Bessemer Venture Partners, where she invests in seed to growth healthcare and life sciences companies. She is the co-author of State of Health Tech report, Benchmarks for Growing Health Tech Business, and how to scale health tech businesses to $100M and beyond, a study of 100+ best-in-class companies to understand key metrics relevant for scalability in healthcare software and tech-enabled services.
Sofia began her career as a consultant at Bain and Company, where she worked on strategy, operations, and due diligence projects across healthcare and technology.
Prior to joining Bessemer, she was an investor at BoxGroup Ventures and the co-founder and co-president of Nucleate, a national life sciences entrepreneurship program helping PhDs, Post-docs, and students commercialize scientific projects.
Sofia earned her MBA from Harvard Business School and her BA with high honors in Chemistry from Harvard University. While in school, she conducted research alongside Bob Langer, a serial entrepreneur and one of 12 Institute professors at MIT widely recognized for his contributions to drug delivery and tissue engineering fields.
She was born and raised in Guatemala, went to boarding school in Singapore for the last few years of high school, and has traveled to over 35 countries. In her free time, she enjoys listening and dancing to reguetón and traveling to new places with her fiancé Alex.
Morgan Cheatham:
Morgan Cheatham is a vice president with Bessemer Venture Partners in the NYC office where he focuses on healthcare and life sciences investments from seed to growth stages. He specializes across the value chain spanning software, therapeutics, services, and diagnostics, to improve patient care from bench to bedside and leads investing efforts in biomedical artificial intelligence.
Select investments in his portfolio include Abridge, Hinge Health, Seismic Therapeutic, Headspace Health (fka Ginger), Subtle Medical, Turquoise Health, Productboard, Plenful, Groups Recover Together, Ansible Health, US Health Partners, and FOLX Health, where he serves on the board and previously served as Interim CEO. He was awarded Forbes 30U30 for Venture Capital and the National Venture Capital Association Rising Star Award (2023).
Morgan has spearheaded the development of many roadmaps at Bessemer, authoring notable reports such as Bessemer's 10 Laws of Healthcare and Six Imperatives for AI-first Companies.
Morgan is pursuing medical training at The Warren Alpert Medical School of Brown University with a research focus on artificial intelligence in biomedicine. His research has been published in leading academic journals including Nature Medicine, NEJM AI, and PLOS. Morgan is on the Editorial Team at NEJM AI and a Board Director at Coalition for Health AI. Prior to Bessemer, he worked in data science roles in healthcare technology. He earned his bachelor of science in Computational Decision Sciences from Brown University.
Listen